ARCHIVES

Alimta Granted Approval As NSCLC Continuation Therapy

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

July 26, 2013

Study Opens For Women At Risk of Ovarian Cancer

October 29, 2004

Concept Approved For New Quality Assurance Center

May 14, 1982

Gemcitabine Improves DFS In Resected Pancreatic Cancer

June 24, 2005

Breast Cancer action Plan Calls For More federal Coordination, Patient Participation

March 23, 1994

DCT Board Okays Concepts For New Radiation Studies

June 12, 1987